Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
复制标题
DOI：
10.1002/cam4.3278
复制
发表时间：
2020-09
期刊：
影响因子：
4
通讯作者：
Press MF
中科院分区：
文献类型：
--
作者：
Toppmeyer DL;Press MF
乳腺癌是女性中最常见的癌症，大约71%的癌症是激素受体阳性（HR+）和人表皮生长因子受体2非扩增（HER 2阴性）。乳腺癌的发病机制与几种信号通路的失调有关，包括磷脂酰肌醇-3-激酶（PI 3 K）通路。PIK 3CA是编码PI 3 K催化亚基p110α的基因，在20%-40%的乳腺癌患者中发生突变。已经开发了几种PI 3 K抑制剂，其中一种，alpelisib，最近被批准用于PIK 3CA突变，HR+，HER 2阴性的晚期乳腺癌。在临床研究中使用多种类型的测定和方法来确定癌症中的PIK 3CA状态。此外，在临床实践中PIK 3CA检测需要考虑几个因素，包括检测方法的选择、样本来源和检测时间。在这篇综述中，我们讨论了使用PIK 3CA作为生物标志物来指导HR+，HER 2阴性晚期乳腺癌患者的治疗决策，以及实际考虑和测试建议。 PIK 3CA可用作生物标志物，指导HR+、HER 2阴性ABC患者的治疗决策。PIK 3CA突变可通过组织或液体活检使用基于PCR或NGS的测定进行评估。
Breast cancer is the most common cancer in women, and approximately 71% of carcinomas are hormone receptor‐positive (HR+) and human epidermal growth factor receptor 2‐not‐amplified (HER2‐negative). Pathogenesis of breast cancer is associated with dysregulation of several signaling pathways, including the phosphatidylinositol‐3‐kinase (PI3K) pathway. PIK3CA, the gene encoding PI3K catalytic subunit p110α, is mutated in 20%‐40% of breast cancer patients. Several PI3K inhibitors have been developed and one, alpelisib, was recently approved for use in PIK3CA‐mutated, HR+, HER2‐negative advanced breast cancer. There are numerous types of assays and methods used in clinical studies to determine PIK3CA status in cancers. Additionally, there are several factors to consider for PIK3CA testing in clinical practice, including choice of assay, source of sample, and test timing. In this review, we discuss the use of PIK3CA as a biomarker to guide treatment decisions in patients with HR+, HER2‐negative advanced breast cancer, as well as practical considerations and recommendations for testing. PIK3CA may be used as a biomarker to guide treatment decisions in patients with HR+, HER2‐negative ABC. PIK3CA mutation may be assessed through either tissue or liquid biopsy using PCR‐ or NGS‐based assays.
登录
查看更多内容
DOI：
10.1186/bcr3493
发表时间：
2013-10-01
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Eccles SA;Aboagye EO;Ali S;Anderson AS;Armes J;Berditchevski F;Blaydes JP;Brennan K;Brown NJ;Bryant HE;Bundred NJ;Burchell JM;Campbell AM;Carroll JS;Clarke RB;Coles CE;Cook GJ;Cox A;Curtin NJ;Dekker LV;Silva Idos S;Duffy SW;Easton DF;Eccles DM;Edwards DR;Edwards J;Evans D;Fenlon DF;Flanagan JM;Foster C;Gallagher WM;Garcia-Closas M;Gee JM;Gescher AJ;Goh V;Groves AM;Harvey AJ;Harvie M;Hennessy BT;Hiscox S;Holen I;Howell SJ;Howell A;Hubbard G;Hulbert-Williams N;Hunter MS;Jasani B;Jones LJ;Key TJ;Kirwan CC;Kong A;Kunkler IH;Langdon SP;Leach MO;Mann DJ;Marshall JF;Martin L;Martin SG;Macdougall JE;Miles DW;Miller WR;Morris JR;Moss SM;Mullan P;Natrajan R;O'Connor JP;O'Connor R;Palmieri C;Pharoah PD;Rakha EA;Reed E;Robinson SP;Sahai E;Saxton JM;Schmid P;Smalley MJ;Speirs V;Stein R;Stingl J;Streuli CH;Tutt AN;Velikova G;Walker RA;Watson CJ;Williams KJ;Young LS;Thompson AM
通讯作者：
Thompson AM
DOI：
10.1158/1055-9965.epi-16-0889
发表时间：
2017-06
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Mariotto AB;Etzioni R;Hurlbert M;Penberthy L;Mayer M
通讯作者：
Mayer M
DOI：
10.1007/s40883-019-00141-2
发表时间：
2021-09-01
影响因子：
2.6
作者：
Bratulic, Sinisa;Gatto, Francesco;Nielsen, Jens
通讯作者：
Nielsen, Jens
影响因子：
--
作者：
Hammond, M. Elizabeth H.;Hayes, Daniel F.;Temin, Sarah
通讯作者：
Temin, Sarah
DOI：
10.1016/s1470-2045(17)30376-5
发表时间：
2017-07
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Baselga J;Im SA;Iwata H;Cortés J;De Laurentiis M;Jiang Z;Arteaga CL;Jonat W;Clemons M;Ito Y;Awada A;Chia S;Jagiełło-Gruszfeld A;Pistilli B;Tseng LM;Hurvitz S;Masuda N;Takahashi M;Vuylsteke P;Hachemi S;Dharan B;Di Tomaso E;Urban P;Massacesi C;Campone M
通讯作者：
Campone M